Richard Hurd Email and Phone Number

Consulting firm specializing in the establishment of essential Medical Affairs capabilities in clinical stage, pre-commercial biotechnology companies with an emphasis on Rare Disease and Oncology.Formed partnership with Glean Insights, LLC to drive innovation and excellence in the field of Medical Affairs through the establishment of core Medical Affairs strategies and through the implementation of critical capabilities. Work collaboratively on selected projects to provide a more comprehensive portfolio of services to our clients.

Senior Medical Affairs leader with responsibility for the development and execution of a globally-aligned medical launch strategy including field development, HCP engagement strategies, change management, and operations capability expansion.

Headed Medical Affairs activities involving headcount planning, lifecycle management, budgeting, and strategic engagement across the portfolio with five breakthrough indication launches.Secured unplanned resourcing for a field medical team expansion and division, creating focal expertise which supported both rare disease and oncology portfolios respectively.Managed a team spanning various roles, building a capabilities continuum and developing a framework for personnel regarding promotional ladders.Oversaw an overhaul of the Medical Affairs strategic planning process, simplifying core strategies, tactics, and goals as well as highlighting key medical successes across the portfolio.Worked cross-functionally with and influenced decision-making of Commercial and R&D organizations to attain alignment across US Medical and key opinion leader (KOL) engagement strategies.

Provided Medical Affairs leadership, managing a Global Medical Services team and budget across medical communications, information, operations, early access, medical content development, and training for a first-in-class platform siRNA technology focused on rare disease.Devised comprehensive data communications strategies across all therapeutic areas, maintaining accountability for the global execution of the strategic publication and congress plan.Drove cross-functional coordination, aligning data communication strategies with Global/Regional Medical Directors, clinical development, clinical operations, corporate communications, and commercial leadership.

A global role with responsibility for Early Access Programs (Pre-Approval Access and Compassionate Use), Investigator Initiated Studies (IIS), Medical Affairs led Clinical Research, and the development of corporate strategies regarding registry development across the Alnylam portfolio. Responsible for the initiation and execution of a pan-portfolio Early Access Program including both Pre-Approval Access Programs and Compassionate Use provision; Managed all clinical/ medical operations in regard to the implementation of the Patisiran Pre-Approval Access Program and created a model for all future pipeline products; Successfully piloted the first pre-approval access program for Alnylam, with over 330 patients treated across 11 countries and 45 institutions.Created the platform-wide IIS program from review through publication to support late stage pipeline candidates and to manage the execution of existing sponsored studies. Developed and executed a global 3,000 patient screening study to identify patients with porphyria. Oversaw all Medical Affairs Operations, including Grants, Budget planning, Commercial/ Medical Revie

Responsible for creating a field medical affairs team to support the launch of Xofigo® (Radium-223), a novel alpha-pharmaceutical for the treatment of metastatic castrate resistant prostate cancer. Served as a key member of the US Management and Medical Affairs teams, building and managing a fully integrated and cross-functional field Medical Affairs team of seven MSLs that supported the pre-, peri-, and post-launch needs for a novel therapeutic.Established a collaborative partnership with Bayer Pharmaceuticals, applying negotiation skills to secure key wins regarding budget, territory allocation, and field responsibilities.Created, implemented, and enforced a corporate compliance program for the field Medical Affairs team to ensure adherence to OIG, PhRMA, ACCME, and FDA/OPDP guidelines.Algeta was acquired by its commercial partner, Bayer Pharmaceuticals.

Worked in medical affairs in the field supporting the launch of the first immunotherapy used to treat prostate cancer by interfacing with key opinion leaders (KOLs) across CT, RI, MA, VT, NH, and ME, holding responsibility for Provenge as well as multiple pipeline agents using a platform technology.

A diverse role focused on the treatment of Non-Hodgkin’s Lymphoma that required cross-team contribution to clinical development, business development, and regulatory review in addition to the traditional responsibilities of a MSL. Responsible for Zevalin (ibritumomab tiuxetan), Fusilev (levo-leucovorin), and belinostat, a developmental histone deacetylase inhibitor.

Oncology sales in both Hospital and Clinic settings covering the state of Connecticut. A role that required complex knowledge of the oncology market and reimbursement landscape. Responsible for Doxil (pegylated liposomal doxorubicin), Velcade (bortezomib), Procrit (epoetin alfa), and CellSearch (diagnostic)

Oncology position dedicated to clinical research and medical education dissemination. Worked with both investigator initiated, company sponsored, and cooperative group trials covering a territory spanning CT, NY, RI, MA, and Northern PA.

A two-fold role focused on domestic and strategic support of pre-marketing initiatives involved with the launch of Zarnestra (tipifarnib), a first in class targeted oncology agent, as well as identifying and appraising acquisition prospects based on strategic fit and potential market performance.

Post-doctoral training in the discipline of pharmaceutical market research.Fellowship seminars, undergraduate teaching responsibilities